CEO Total Pay
$2.7M
FY2024 Summary Compensation, below median
ENTA FY2024 SEC EDGAR DEF 14A
Enanta Pharmaceuticals Inc CEO pay ratio
The CEO earned $2.7M in FY2024 against median worker pay of $208,253 · Chemicals & Pharmaceuticals.
- State
- MA
- Filing date
- 2025-01-27
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2024
Data updated August 2026
Subscribe to Enanta Pharmaceuticals Inc CEO pay filing updates (RSS)
CEO-to-worker pay ratio
2,023:1
Extreme (bar capped at 1000:1; actual ratio shown above)
CEO pay
$2.7M
Median worker
$208,253
Latest filing FY2024. This company's newest DEF 14A on file is for FY2024, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Enanta Pharmaceuticals Inc reported a 2,023:1 CEO-to-worker pay ratio in FY2024 - above the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 2,023:1
- FY2024 disclosed
- CEO total
- $2.7M
- Summary Compensation Table total
- Median worker
- $208,253
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2024
A component-level pay breakdown is not reported in Enanta Pharmaceuticals Inc's structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Enanta Pharmaceuticals Inc
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2024. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 2,023:1
- FY2024
- vs prior FY
- +1990:1
- from FY2023 33:1
- CEO $ YoY
- -66%
- $2.7M latest
- Filings shown
- 4
- FY2021–2024
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $5.3M | - | $230,731 | 23:1 | - |
| 2022 | $7.3M | +37% | $249,345 | 29:1 | +6:1 |
| 2023 | $7.9M | +8% | $235,891 | 33:1 | +4:1 |
| 2024 | $2.7M | -66% | $208,253 | 2,023:1 | +1990:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1177648, FY2021–2024. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
2,023:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$2.7M
Companies in Industry
168
vs. Industry Median
Above
Enanta Pharmaceuticals Inc: upper-tail Item 402(u) ratio
Enanta Pharmaceuticals Inc stamps MEGA · MID$ at 2,023:1 with $2.7M CEO total in FY2024. the CEO earned 2023× the median employee ($208,253) in FY2024.
At $208,253 median worker pay (ELITE-MED), the MEGA stamp means roughly 2023 years of median wages to match one CEO year.
Pay Ratio
2,023:1
Outlier, top decile
What FY2024 shows for Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc stamps MEGA · MID$ at 2,023:1 with $2.7M CEO total in FY2024. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Enanta Pharmaceuticals Inc's $2.7M CEO total is at or below the $7.9M industry median CEO pay.
Enanta Pharmaceuticals Inc stamps MEGA · MID$ · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2024
- Total Compensation
- $2.7M
- Median Employee Pay
- $208,253
- Pay Ratio
- 2,023:1
- Filing Date
- 2025-01-27
Company Info
- Ticker
- ENTA
- CIK
- 1177648
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- MA
SEC EDGAR DEF 14A for CIK 1177648, FY2024. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Enanta Pharmaceuticals Inc stamps MEGA · MID$ at 2,023:1 with $2.7M CEO total in FY2024.
Read with Enanta Pharmaceuticals Inc
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MEGA · MID$ · ELITE-MED.
Community Financial System, Inc. · MID$
ABS(ceo_total_comp) peer at $2.7M (Δ $6K heavier vs Enanta Pharmaceuticals Inc); MODEST · PAR-MED vs this page's MEGA · MID$ · ELITE-MED.
Old Second Bancorp Inc · MID$
ABS(ceo_total_comp) peer at $2.7M (Δ $6K heavier vs Enanta Pharmaceuticals Inc); MODEST · PAR-MED vs this page's MEGA · MID$ · ELITE-MED.
Monro, Inc. · MID$
ABS(ceo_total_comp) peer at $2.7M (Δ $7K lighter vs Enanta Pharmaceuticals Inc); MODEST · PAR-MED vs this page's MEGA · MID$ · ELITE-MED.
Stellar Bancorp, Inc. · MID$
ABS(ceo_total_comp) peer at $2.7M (Δ $8K heavier vs Enanta Pharmaceuticals Inc); MODEST · HIGH-MED vs this page's MEGA · MID$ · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Enanta Pharmaceuticals Inc stamps MEGA · MID$ · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · MEGA
See where MEGA · MID$ packages sit on the national leaderboard after reading Enanta Pharmaceuticals Inc.
Highest-paid CEOs · MEGA
Enanta Pharmaceuticals Inc's MEGA stamp is in the upper tail - the highest-paid list shows how dollar packages and ratios diverge.
Data sourced from SEC EDGAR DEF 14A for Enanta Pharmaceuticals Inc (CIK 1177648), FY2024. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.